Literature DB >> 10358773

Degradation of cell proteins and the generation of MHC class I-presented peptides.

K L Rock1, A L Goldberg.   

Abstract

Major histocompatibility complex (MHC) class I molecules display on the cell surface 8- to 10-residue peptides derived from the spectrum of proteins expressed in the cells. By screening for non-self MHC-bound peptides, the immune system identifies and then can eliminate cells that are producing viral or mutant proteins. These antigenic peptides are generated as side products in the continual turnover of intracellular proteins, which occurs primarily by the ubiquitin-proteasome pathway. Most of the oligopeptides generated by the proteasome are further degraded by distinct endopeptidases and aminopeptidases into amino acids, which are used for new protein synthesis or energy production. However, a fraction of these peptides escape complete destruction and after transport into the endoplasmic reticulum are bound by MHC class I molecules and delivered to the cell surface. Herein we review recent discoveries about the proteolytic systems that degrade cell proteins, how the ubiquitin-proteasome pathway generates the peptides presented on MHC-class I molecules, and how this process is stimulated by immune modifiers to enhance antigen presentation.

Mesh:

Substances:

Year:  1999        PMID: 10358773     DOI: 10.1146/annurev.immunol.17.1.739

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  191 in total

1.  gamma-Interferon decreases the level of 26 S proteasomes and changes the pattern of phosphorylation.

Authors:  S Bose; P Brooks; G G Mason; A J Rivett
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

2.  Subcellular localization of proteasomes and their regulatory complexes in mammalian cells.

Authors:  P Brooks; G Fuertes; R Z Murray; S Bose; E Knecht; M C Rechsteiner; K B Hendil; K Tanaka; J Dyson; J Rivett
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other.

Authors:  P J Goulder; Y Tang; S I Pelton; B D Walker
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.

Authors:  G Dadaglio; Z Moukrim; R Lo-Man; V Sheshko; P Sebo; C Leclerc
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

5.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 6.  The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells.

Authors:  H Singh-Jasuja; N Hilf; H U Scherer; D Arnold-Schild; H G Rammensee; R E Toes; H Schild
Journal:  Cell Stress Chaperones       Date:  2000-11       Impact factor: 3.667

Review 7.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

8.  Contrasting requirements for ubiquitylation during Fc receptor-mediated endocytosis and phagocytosis.

Authors:  James W Booth; Moo-Kyung Kim; Andrzej Jankowski; Alan D Schreiber; Sergio Grinstein
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

9.  A basolateral sorting motif in the MICA cytoplasmic tail.

Authors:  Hiroshi Suemizu; Mirjana Radosavljevic; Minoru Kimura; Sotaro Sadahiro; Shinichi Yoshimura; Seiamak Bahram; Hidetoshi Inoko
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

10.  Human T-cell leukemia virus type 1 Tax protein binds to assembled nuclear proteasomes and enhances their proteolytic activity.

Authors:  J Hemelaar; F Bex; B Booth; V Cerundolo; A McMichael; S Daenke
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.